Sermorelin, also known as GRF 1-29 (Growth Hormone-Releasing Factor 1-29), is a synthetic peptide comprising the first 29 amino acids of endogenous human GHRH. It represents the shortest fully active fragment of GHRH capable of binding to and activating the GHRH receptor (GHRHR) on somatotroph cells within the anterior pituitary gland, thereby stimulating the pulsatile release of endogenous growth hormone (GH).
In research settings, Sermorelin has been extensively investigated as a tool for studying the hypothalamic-pituitary-GH axis, age-related GH decline, and somatotroph cell function. Its mechanism of action involves direct agonism at the GHRHR, triggering intracellular cAMP signalling cascades that promote GH biosynthesis and secretion in a physiologically regulated manner.
Key research applications include the study of GH deficiency models, neuroendocrine signalling, metabolic regulation, sleep architecture, and cellular repair processes. Compared to exogenous GH administration, Sermorelin’s action preserves natural feedback mechanisms, making it a valuable tool in endocrinological research.
Store at -20°C; protect from light and moisture. Reconstitute with bacteriostatic water prior to use.
Molecular Formula
C₁₄₉H₂₄₆N₄₄O₄₂S
Molecular Weight
3357.9 g/mol
Purity
>98%
CAS Number
86168-78-7
Form
Lyophilised Powder
Research Applications
Neuroendocrine signalling, Growth hormone axis research, GH deficiency models, Metabolic regulation studies, Sleep architecture research, Cellular repair and regeneration
For research purposes only. Not for human use.
Reviews
There are no reviews yet.